ADMAADMA Biologics, Inc.
$10.36-35% 1Y
$10.36
$7.6052 weeks$20.38
ADMA as reported
ADMA Biologics, Inc. reported $512M of revenue over the trailing twelve months, +8.0% on the year before. 11 reported series are charted on this page, each one as filed.
$512M
Revenue, trailing twelve months · to Q2 2026 · +8.0% against the twelve months before
- Net income
- $169M
Net income · −19% year on year · trailing twelve months to Q2 2026
- Free cash flow
- $116M
Free cash flow · +77% year on year · trailing twelve months to Q2 2026
- Operating margin
- 44%
Operating margin · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $512M | +8.0% | Q2 2026 |
| Net income | $169M | −19% | Q2 2026 |
| EPS | $0.70 | −19% | Q2 2026 |
| Gross margin | 65% | n/a | Q2 2026 |
| Operating margin | 44% | n/a | Q2 2026 |
| Net margin | 33% | n/a | Q2 2026 |
| ROE | 41% | n/a | Q2 2026 |
| ROA | 27% | n/a | Q2 2026 |
| ROIC | 35% | n/a | Q2 2026 |
| Free cash flow | $116M | +77% | Q2 2026 |
| P/E | 14.8 | n/a | today |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
ADMA Biologics, Inc. (ADMA) · Revenue and profitRevenue and profitADMA Biologics, Inc. (ADMA)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
